Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$138.37
-1.4%
$141.92
$128.51
$238.00
$20.25B0.011.31 million shs1.09 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$820.30
-0.2%
$842.43
$711.40
$972.53
$777.78B0.343.66 million shs2.05 million shs
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$1.65
-2.9%
$2.51
$1.63
$42.20
$79.71M-1.242.96 million shs1.45 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-1.47%-0.74%-2.18%-7.26%-35.13%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.57%-2.51%-8.90%+4.98%+5.58%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-2.86%-38.41%-29.75%-32.00%-91.67%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biogen Inc. stock logo
BIIB
Biogen
4.9003 of 5 stars
4.25.00.03.73.42.51.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.7992 of 5 stars
2.45.03.34.03.42.51.9
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3.8785 of 5 stars
3.33.00.04.71.60.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.43
Hold$213.3354.18% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7223.09% Upside
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.50
Moderate Buy$54.503,203.03% Upside

Current Analyst Ratings Breakdown

Latest BIIB, LLY, and SAVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/4/2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
2/18/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$138.00 ➝ $135.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$244.00 ➝ $224.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$156.00 ➝ $139.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$281.00 ➝ $245.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$192.00 ➝ $157.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$160.00 ➝ $145.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$231.00 ➝ $225.00
(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.68B2.09$22.72 per share6.09$114.71 per share1.21
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.27$13.37 per share61.34$15.05 per share54.50
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.26 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$11.1912.378.381.5116.87%14.98%8.76%4/23/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.0526.361.4023.51%85.24%16.19%5/1/2025 (Estimated)
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$97.22M-$1.45N/AN/AN/AN/A-88.05%-64.98%5/9/2025 (Estimated)

Latest BIIB, LLY, and SAVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2025N/A
Biogen Inc. stock logo
BIIB
Biogen
$3.59N/AN/AN/A$2.25 billionN/A
3/3/2025Q4 2024
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$0.68-$0.57+$0.11-$0.57N/AN/A
2/12/2025Q4 2024
Biogen Inc. stock logo
BIIB
Biogen
$3.43$3.44+$0.01$1.83$2.42 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.27
1.35
0.90
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
3.55
3.55

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
8,720146.38 million146.14 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million43.78 millionOptionable

Recent News About These Companies

End of the line for Cassava's troubled Alzheimer's programme
Cassava Sciences announces Phase 3 REFOCUS-ALZ did not meet primary endpoint
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Are you fooling yourself?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biogen stock logo

Biogen NASDAQ:BIIB

$138.37 -1.96 (-1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$138.18 -0.19 (-0.13%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$820.30 -1.37 (-0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$815.39 -4.91 (-0.60%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$1.65 -0.05 (-2.94%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 +0.04 (+2.12%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.